Skip to main content

Table 6 Heart rate in the three study groups

From: Acute hypervolemic hemodilution combined with controlled hypotension to minimize blood loss during operations of spine fusion: remifentanil versus magnesium sulfate

 

Group I

(N = 18)

Group I

(N = 20)

Group III

(N = 19)

p value

Baseline (before induction)

81.6 ± 10.1

82.4 ± 12.1

84.2 ± 7.9

0.587

5 min after AHH start

79.3 ± 12.2

63.3 ± 13.2*

68.2 ± 10.2*

0.0004

10 min after AHH start

76.2 ± 9.6

65.1 ± 10.4*

68.4 ± 11.2*

0.0016

15 min after AHH start

78.7 ± 8.9

65.9 ± 11.5*

67.1 ± 10.7*

0.0010

30 min after AHH start

75.4 ± 11.2

62.8 ± 9.4*

65.4 ± 9.5*

0.0059

45 min after AHH start

78.9 ± 10.5

61.4 ± 10.7*

63.2 ± 12.4*

< 0.0001

60 min after AHH start

76.3 ± 12.6

61.1 ± 8.3*

64.8 ± 13.3*

< 0.0001

90 min after AHH start

79.9 ± 9.3

62.7 ± 11.3*

66.4 ± 11.8*

< 0.0001

2 h after AHH start

80.2 ± 10.9

58.5 ± 12.5*

59.7 ± 10.6*

< 0.000

3 h after AHH start

81.3 ± 10.7

61.4 ± 9.9*

62.6 ± 9.3*

< 0.0001

  1. -Data are presented as mean ± SD. p < 0.05 is considered significant.
  2. -*Significant in group II or group III in relation to group I